Dr Reddy’s Labs Q1 Results FY27: Net Profit Plunges 68.7% to Rs 444 Crore, Misses Estimates Sharply

Dr Reddy’s Labs Q1 results FY27 were announced on Wednesday, 22 July 2026, with the pharmaceutical major’s Dr Reddy’s Labs Q1 results FY27 showing a consolidated net profit of Rs 444 crore for the quarter ended 30 June 2026, down 68.7% from Rs 1,418 crore in the year ago quarter and well short of the Street estimate of Rs 737 crore. Revenue declined 5.5% to Rs 8,100 crore, also missing the estimate of Rs 8,221 crore.

Shares of Dr Reddy’s Laboratories fell 1.92% to Rs 1,182.80 on the NSE on the results day, as the market reacted to a sharp miss across every key metric.

Click Here – Get Free Investment Predictions

Dr Reddy’s Labs Q1 Results FY27 Key Takeaways

Here are the most important numbers from the Dr Reddy’s Labs Q1 results FY27 at a glance.

• Net Profit (PAT): Rs 444 Cr in Q1 FY27 versus Rs 1,418 Cr in Q1 FY26, down 68.7% year on year, against a Street estimate of Rs 737 Cr.
• Revenue: Rs 8,100 Cr in Q1 FY27 versus Rs 8,572 Cr in Q1 FY26, down 5.5% year on year, against an estimate of Rs 8,221 Cr.
• EBITDA: Rs 861 Cr in Q1 FY27 versus Rs 2,173 Cr in Q1 FY26, down 60.4% year on year, against an estimate of Rs 1,398 Cr.
• EBITDA margin collapsed to 10.6% from 25.3% a year ago, well below the 17% estimate.
• Global Generics revenue, which includes the key US business, fell 4.8% to Rs 7,208 Cr.
• Dr Reddy’s share price fell 1.92% to Rs 1,182.80 on the NSE on the results day.

Dr Reddy’s Labs Q1 Results FY27 Financial Highlights

The table below summarises the consolidated numbers reported in the Dr Reddy’s Labs Q1 results FY27 against both the year ago quarter and Street estimates.

Metric	Q1 FY27 Actual	Q1 FY26	Street Estimate
Revenue	Rs 8,100 Cr	Rs 8,572 Cr	Rs 8,221 Cr
EBITDA	Rs 861 Cr	Rs 2,173 Cr	Rs 1,398 Cr
Net Profit (PAT)	Rs 444 Cr	Rs 1,418 Cr	Rs 737 Cr

All figures are on a consolidated basis as reported for the quarter ended 30 June 2026. Other income rose to Rs 355 crore from Rs 290 crore a year ago, providing some cushion to an otherwise weak quarter.

Dr Reddy’s Labs Q1 Results FY27 Performance Analysis

Get Personalised Guidance from a SEBI-Registered Investment Advisor

A steep margin collapse defines the Dr Reddy’s Labs Q1 results FY27. The EBITDA margin fell to 10.6% from 25.3% a year ago, nearly halving even against the Street’s own reduced estimate of 17%, showing analysts had underestimated the scale of the pressure facing the business this quarter.

Brokerages had flagged ahead of the results that profit would likely decline on lower contribution from key products and intense US generics competition. The Global Generics segment, which includes the US business, saw revenue decline 4.8% to Rs 7,208 crore, consistent with this pressure.

Separately, the company disclosed on 9 July 2026 an out-of-specification API issue in certain semaglutide batches, delaying commercial supplies while it investigates, with no stated impact on patient safety or filings. This likely added to the quarter’s pressure.

Dr Reddy’s Labs Q1 Results FY27: Key Business Factors

1. US Generics Pricing and Competitive Pressure

Intense competition and pricing erosion in the US generics market, the company’s largest revenue contributor, is the primary driver cited by analysts behind the sharp margin decline in the Dr Reddy’s Labs Q1 results FY27.

2. Semaglutide Supply Delay

The disclosed API quality issue delaying commercial supply of the company’s semaglutide metabolic therapy product removed an anticipated revenue contributor from the quarter, adding to the topline and margin pressure.

3. Broad Based Miss Against Estimates

Every key metric, revenue, EBITDA and PAT, missed Street estimates by a wide margin, suggesting the scale of the pressure was underappreciated going into the results.

Dividend Details

Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company’s official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.

Dr Reddy’s Labs Q1 Results FY27 Outlook for the Full Year

After the results, the key questions for FY27 are how quickly the semaglutide supply issue resolves, whether US pricing pressure stabilises, and what new launches management can point to as offsets. Given the scale of the miss, the earnings call commentary will be watched closely for margin recovery guidance.

Dr Reddy’s Labs Stock Performance After the Q1 Results

Download the Univest iOS App or Univest Android App to track Dr Reddy’s Laboratories live share price and upcoming quarterly results.

Dr Reddy’s share price fell 1.92% to Rs 1,182.80 on the NSE after the Dr Reddy’s Labs Q1 results FY27, as the market absorbed a sharp miss across every reported line.

Investors can compare the trend of the counter with the broader pharma sector to judge how the stock is placed relative to peers after the Dr Reddy’s Labs Q1 results FY27.

Key Risks

Investors going through the fine print of the Dr Reddy’s Labs Q1 results FY27 should also weigh the following risks.

1. Continued US Pricing Pressure

Persistent competitive intensity and pricing erosion in US generics could delay margin recovery beyond current market expectations.

2. Semaglutide Launch Timeline Uncertainty

The resolution timeline for the disclosed API quality issue remains uncertain, and further delays would extend the revenue and margin pressure visible in the Dr Reddy’s Labs Q1 results FY27.

3. Regulatory and Manufacturing Risk

Further US FDA inspection findings or compliance issues at its regulated facilities could add to near term uncertainty.

Conclusion

Dr Reddy’s Labs Q1 results FY27 show a sharp miss with net profit down 68.7% at Rs 444 crore against a Street estimate of Rs 737 crore, driven by US generics pricing pressure and a disclosed semaglutide supply delay. Investors should track the earnings call commentary for a margin recovery timeline and consult a SEBI-registered advisor before acting on the numbers.

Frequently Asked Questions on Dr Reddy’s Labs Q1 Results FY27

When were the Dr Reddy’s Labs Q1 results FY27 announced?

Ans. The Dr Reddy’s Labs Q1 results FY27 were announced on Wednesday, 22 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.

What is the PAT in the Dr Reddy’s Labs Q1 results FY27?

Ans. The consolidated PAT in the Dr Reddy’s Labs Q1 results FY27 stood at Rs 444 crore, down 68.7% from Rs 1,418 crore in Q1 FY26, and well below the Street estimate of Rs 737 crore.

Why did Dr Reddy’s profit fall so sharply in Q1 FY27?

Ans. The Dr Reddy’s Labs Q1 results FY27 reflect intense competition and pricing pressure in the US generics market, the company’s largest revenue segment, along with a disclosed delay in commercial supplies of its semaglutide product due to an active pharmaceutical ingredient quality issue found on 9 July 2026.

What was the EBITDA margin in the Dr Reddy’s Labs Q1 results FY27?

Ans. The EBITDA margin in the Dr Reddy’s Labs Q1 results FY27 collapsed to 10.6% from 25.3% a year ago, well below the Street estimate of 17%.

What happened with Dr Reddy’s semaglutide product?

Ans. The company identified an issue with the active pharmaceutical ingredient used in certain batches of semaglutide, causing it to be out of specification. This is delaying commercial supplies of the metabolic therapy while the company investigates, though it stated there is no impact on patient safety or existing regulatory filings.

How did the share price react to the Dr Reddy’s Labs Q1 results FY27?

Ans. Dr Reddy’s Laboratories share price fell 1.92% to Rs 1,182.80 on the NSE after the Dr Reddy’s Labs Q1 results FY27.

Is the stock a good buy after the Dr Reddy’s Labs Q1 results FY27?

Ans. The Dr Reddy’s Labs Q1 results FY27 show a sharp miss driven by US pricing pressure and a product supply delay, both factors investors should track for signs of resolution. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.

Where can I verify the Dr Reddy’s Labs Q1 results FY27?

Ans. The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.